{"id":28841,"date":"2025-03-06T20:24:28","date_gmt":"2025-03-06T12:24:28","guid":{"rendered":"https:\/\/flcube.com\/?p=28841"},"modified":"2025-03-06T20:24:32","modified_gmt":"2025-03-06T12:24:32","slug":"sandozs-q4-2024-results-show-strong-biosimilar-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=28841","title":{"rendered":"Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth"},"content":{"rendered":"\n

Switzerland-headquartered Sandoz (SWX: SDZ<\/a>) has released its Q4 2024 financial results. The firm’s global revenues rose 9% year-on-year (YOY) in constant currencies to USD 10.7 billion during the year. The firm’s performance improved during the year, with Q4 revenues up 9% YOY to USD 2.7 billion.<\/p>\n\n\n\n

Sales Breakdown<\/strong>
Generic drugs generated USD 7.5 billion in sales, representing a 2% increase. Biosimilars saw significant growth, with sales reaching USD 2.85 billion after a 30% expansion, making them the main growth driver.<\/p>\n\n\n\n

Geographical Performance<\/strong>
Sales in Europe jumped 6% YOY to USD 5.36 billion during the year. In North America, sales surged 15% YOY to USD 2.13 billion. International market sales reached USD 2.56 billion, up 8% YOY.<\/p>\n\n\n\n

Product Launches and Pipeline<\/strong>
Last year saw multiple biosimilars launched to the market, including Tyruko (natalizumab biosimilar), which launched in Germany in January, Hyrimoz (adalimumab), which launched in the US in April, and Pyzchiva (ustekinumab), which launched in Europe in July. Sandoz added five assets to its biosimilar pipeline last year, bringing its total to 28 molecules. These include knockoff versions of pembrolizumab and nivolumab, anti-tumor drugs at late stages. The company also boasts around 450 generics in its portfolio.<\/p>\n\n\n\n

Future Outlook<\/strong>
More biosimilars are expected to launch this year, including Pyzchiva and Tyruko in the US, and Wyost \/ Jubbonti (denosumab) in Europe and the US. Net sales are projected to grow by a mid-single-digit percentage in 2025.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm’s global revenues…<\/p>\n","protected":false},"author":1,"featured_media":28842,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,747,886],"class_list":["post-28841","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-sandoz","tag-swx-sdz"],"yoast_head":"\nSandoz's Q4 2024 Results Show Strong Biosimilar Growth - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm's global revenues rose 9% year-on-year (YOY) in constant currencies to USD 10.7 billion during the year. The firm's performance improved during the year, with Q4 revenues up 9% YOY to USD 2.7 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=28841\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sandoz's Q4 2024 Results Show Strong Biosimilar Growth\" \/>\n<meta property=\"og:description\" content=\"Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm's global revenues rose 9% year-on-year (YOY) in constant currencies to USD 10.7 billion during the year. The firm's performance improved during the year, with Q4 revenues up 9% YOY to USD 2.7 billion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=28841\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-06T12:24:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-06T12:24:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0601-1-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28841#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28841\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth\",\"datePublished\":\"2025-03-06T12:24:28+00:00\",\"dateModified\":\"2025-03-06T12:24:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28841\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28841#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0601-1-png.avif\",\"keywords\":[\"Finanical Reports\",\"Sandoz\",\"SWX: SDZ\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28841#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28841\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=28841\",\"name\":\"Sandoz's Q4 2024 Results Show Strong Biosimilar Growth - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28841#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28841#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0601-1-png.avif\",\"datePublished\":\"2025-03-06T12:24:28+00:00\",\"dateModified\":\"2025-03-06T12:24:32+00:00\",\"description\":\"Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm's global revenues rose 9% year-on-year (YOY) in constant currencies to USD 10.7 billion during the year. The firm's performance improved during the year, with Q4 revenues up 9% YOY to USD 2.7 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28841#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28841\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28841#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0601-1-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0601-1-png.avif\",\"width\":1080,\"height\":608,\"caption\":\"Sandoz's Q4 2024 Results Show Strong Biosimilar Growth\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28841#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sandoz's Q4 2024 Results Show Strong Biosimilar Growth - Insight, China's Pharmaceutical Industry","description":"Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm's global revenues rose 9% year-on-year (YOY) in constant currencies to USD 10.7 billion during the year. The firm's performance improved during the year, with Q4 revenues up 9% YOY to USD 2.7 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=28841","og_locale":"en_US","og_type":"article","og_title":"Sandoz's Q4 2024 Results Show Strong Biosimilar Growth","og_description":"Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm's global revenues rose 9% year-on-year (YOY) in constant currencies to USD 10.7 billion during the year. The firm's performance improved during the year, with Q4 revenues up 9% YOY to USD 2.7 billion.","og_url":"https:\/\/flcube.com\/?p=28841","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-06T12:24:28+00:00","article_modified_time":"2025-03-06T12:24:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0601-1-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=28841#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=28841"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth","datePublished":"2025-03-06T12:24:28+00:00","dateModified":"2025-03-06T12:24:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=28841"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=28841#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0601-1-png.avif","keywords":["Finanical Reports","Sandoz","SWX: SDZ"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=28841#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=28841","url":"https:\/\/flcube.com\/?p=28841","name":"Sandoz's Q4 2024 Results Show Strong Biosimilar Growth - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=28841#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=28841#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0601-1-png.avif","datePublished":"2025-03-06T12:24:28+00:00","dateModified":"2025-03-06T12:24:32+00:00","description":"Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm's global revenues rose 9% year-on-year (YOY) in constant currencies to USD 10.7 billion during the year. The firm's performance improved during the year, with Q4 revenues up 9% YOY to USD 2.7 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=28841#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=28841"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=28841#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0601-1-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0601-1-png.avif","width":1080,"height":608,"caption":"Sandoz's Q4 2024 Results Show Strong Biosimilar Growth"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=28841#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0601-1-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28841"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28841\/revisions"}],"predecessor-version":[{"id":28843,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28841\/revisions\/28843"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/28842"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}